Trading Report: Theravance Biopharma Inc. (TBPH) Downgraded by Robert W. Baird to “Underperform”

Theravance Biopharma Inc. (TBPH) Downgraded by Robert W. Baird to “Underperform”

Robert W. Baird cut shares of Theravance Biopharma Inc. (NASDAQ:TBPH) from a neutral rating to an underperform rating in a report published on Wednesday morning. The firm currently has $24.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $19.00.

A number of other brokerages have also recently issued reports on TBPH. Zacks Investment Research raised Theravance Biopharma from a hold rating to a buy rating and set a $41.00 price objective for the company in a report on Tuesday, October 4th. Guggenheim reissued a positive rating and set a $40.00 price objective on shares of Theravance Biopharma in a report on Monday, September 19th. Evercore ISI began coverage on Theravance Biopharma in a report on Monday, August 29th. They set a buy rating and a $41.00 price objective for the company. Bank of America Corp. cut Theravance Biopharma from a neutral rating to an underperform rating in a report on Wednesday, August 3rd. Finally, Leerink Swann reissued a buy rating and set a $31.00 price objective on shares of Theravance Biopharma in a report on Tuesday, August 9th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. Theravance Biopharma presently has an average rating of Hold and a consensus price target of $35.40.

Theravance Biopharma (NASDAQ:TBPH) traded down 0.365% during trading on Wednesday, hitting $31.395. 68,830 shares of the stock traded hands. The stock’s market cap is $1.50 billion. The company has a 50-day moving average price of $32.99 and a 200 day moving average price of $25.20. Theravance Biopharma has a one year low of $12.75 and a one year high of $38.92.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.05) by $0.01. Theravance Biopharma had a negative net margin of 471.82% and a negative return on equity of 70.79%. Analysts expect that Theravance Biopharma will post ($4.03) earnings per share for the current year.

In other news, SVP Brett K. Haumann sold 9,509 shares of the firm’s stock in a transaction on Friday, August 19th. The stock was sold at an average price of $27.97, for a total value of $265,966.73. Following the completion of the sale, the senior vice president now directly owns 197,391 shares in the company, valued at $5,521,026.27. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Bradford J. Shafer sold 49,122 shares of the firm’s stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $27.46, for a total value of $1,348,890.12. Following the completion of the sale, the executive vice president now owns 241,686 shares of the company’s stock, valued at $6,636,697.56. The disclosure for this sale can be found here. 4.70% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in TBPH. BNP Paribas Arbitrage SA raised its stake in shares of Theravance Biopharma by 110.2% in the third quarter. BNP Paribas Arbitrage SA now owns 3,008 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,577 shares during the period. Teacher Retirement System of Texas raised its stake in shares of Theravance Biopharma by 40.2% in the second quarter. Teacher Retirement System of Texas now owns 4,887 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 1,401 shares during the period. PNC Financial Services Group Inc. raised its stake in shares of Theravance Biopharma by 3.3% in the second quarter. PNC Financial Services Group Inc. now owns 5,992 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 192 shares during the period. Bellevue Group AG acquired a new stake in shares of Theravance Biopharma during the first quarter worth $215,000. Finally, Paloma Partners Management Co acquired a new stake in shares of Theravance Biopharma during the second quarter worth $255,000. Institutional investors own 69.89% of the company’s stock.

Theravance Biopharma Company Profile

Related posts

Leave a Comment